Pfizer receives request from FDA for more information on application for lasofoxifene

Posted on: Mon, 19 Jan 2009 10:24:00 EST


Symbols: PFE
Jan 19, 2009 (M2 EQUITYBITES via COMTEX) --
PFE | Quote | Chart | News | PowerRating -- Pfizer Inc (NYSE:PFE), a pharmaceutical company, announced on 16
January that it has received a complete response letter from the US
Food and Drug Administration (FDA) requesting additional information of
the company's application for lasofoxifene.

The company stated that it is reviewing the letter and will cooperate
with the FDA to determine the next step in its application.

The current application for lasofoxifene was submitted by Pfizer on 18
December 2007. An FDA scientific advisory panel voted 9 to 3 that there
is a population of post-menopausal women with osteoporosis for whom the
benefits of lasofoxifene would likely outweigh the risks. The FDA is
not required to follow the panel's advice.

Lasofoxifene is a selective oestrogen receptor modulator (SERM),
currently under review for the treatment of osteoporosis in
post-menopausal women with an increased risk of fracture.

Comments on this story may be sent to admin@m2.com

For full details on Pfizer Inc (PFE) PFE. Pfizer Inc (PFE) has Short Term PowerRatings at TradingMarkets. Details on Pfizer Inc (PFE) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.